HB Wealth Management LLC Has $1.65 Million Position in West Pharmaceutical Services, Inc. $WST

HB Wealth Management LLC lessened its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 25.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,567 shares of the medical instruments supplier’s stock after selling 2,283 shares during the period. HB Wealth Management LLC’s holdings in West Pharmaceutical Services were worth $1,646,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. New York State Teachers Retirement System raised its position in West Pharmaceutical Services by 2.9% during the first quarter. New York State Teachers Retirement System now owns 60,523 shares of the medical instruments supplier’s stock valued at $15,169,000 after purchasing an additional 1,690 shares in the last quarter. Leonteq Securities AG boosted its holdings in shares of West Pharmaceutical Services by 6,314.3% in the 1st quarter. Leonteq Securities AG now owns 449 shares of the medical instruments supplier’s stock valued at $113,000 after purchasing an additional 442 shares in the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its holdings in shares of West Pharmaceutical Services by 56.0% in the 1st quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 30,600 shares of the medical instruments supplier’s stock valued at $7,670,000 after purchasing an additional 10,990 shares in the last quarter. Conestoga Capital Advisors LLC increased its stake in shares of West Pharmaceutical Services by 6.7% in the 1st quarter. Conestoga Capital Advisors LLC now owns 130,970 shares of the medical instruments supplier’s stock valued at $32,826,000 after purchasing an additional 8,179 shares during the last quarter. Finally, Fulton Bank N.A. raised its holdings in shares of West Pharmaceutical Services by 23.4% during the 1st quarter. Fulton Bank N.A. now owns 2,185 shares of the medical instruments supplier’s stock worth $548,000 after buying an additional 415 shares in the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on WST shares. Wolfe Research started coverage on West Pharmaceutical Services in a research note on Monday, June 1st. They issued an “outperform” rating and a $375.00 price objective on the stock. Zacks Research raised West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 13th. Barclays raised shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $310.00 to $400.00 in a report on Tuesday, June 9th. Evercore restated an “outperform” rating and issued a $410.00 price target on shares of West Pharmaceutical Services in a research note on Monday. Finally, Morgan Stanley lifted their price target on shares of West Pharmaceutical Services from $315.00 to $325.00 and gave the company an “equal weight” rating in a report on Friday, May 29th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $351.91.

Insider Activity at West Pharmaceutical Services

In other news, CAO Chad Winters sold 896 shares of the stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $300.67, for a total transaction of $269,400.32. Following the transaction, the chief accounting officer owned 1,523 shares of the company’s stock, valued at $457,920.41. This represents a 37.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Annette F. Favorite sold 2,817 shares of the business’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $305.20, for a total value of $859,748.40. Following the completion of the sale, the vice president directly owned 16,828 shares of the company’s stock, valued at $5,135,905.60. The trade was a 14.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.60% of the stock is currently owned by insiders.

West Pharmaceutical Services Trading Down 0.4%

WST opened at $356.15 on Wednesday. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.71 and a quick ratio of 2.04. West Pharmaceutical Services, Inc. has a fifty-two week low of $206.80 and a fifty-two week high of $367.66. The company’s 50 day moving average price is $324.62 and its two-hundred day moving average price is $280.17. The firm has a market capitalization of $25.16 billion, a price-to-earnings ratio of 47.61, a PEG ratio of 2.99 and a beta of 1.16.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 EPS for the quarter, topping the consensus estimate of $1.68 by $0.45. The firm had revenue of $844.90 million for the quarter, compared to the consensus estimate of $779.67 million. West Pharmaceutical Services had a return on equity of 19.03% and a net margin of 16.85%.The business’s quarterly revenue was up 21.0% compared to the same quarter last year. During the same period in the previous year, the business earned $1.45 EPS. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. As a group, research analysts predict that West Pharmaceutical Services, Inc. will post 8.6 earnings per share for the current year.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.